iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

IRadimed excels in Q4 2022, anticipates strong growth in 2023

IRadimed's Q4 2022 showcased exceptional performance with record revenues and strong earnings, setting the stage for continued growth.
While facing challenges such as margin pressures and tax expenses, the company's optimistic outlook for 2023 presents growth opportunities.
Strategic focus on revenue expansion, margin improvement, and cost management will be key to sustaining profitability and maximizing shareholder value.
Investors can look forward to potential earnings growth and market positioning strength in the upcoming year.

IRadimed reports record revenue and earnings growth, anticipates FDA clearance

IRadimed's Q1 2023 performance was strong, with record revenue and earnings growth. Despite supply chain challenges, the company is optimistic about FDA clearance for a new product and expects pricing trends to remain favorable.

iRadimed posts record revenue and earnings, raises guidance optimistically

iRadimed delivered exceptional financial performance in Q2 2023, achieving record revenue and substantial earnings growth, driven by strong sales across all product categories.
The company's operational efficiency, margin expansion, and strategic initiatives position it well for sustained growth and profitability in the future.
With raised guidance, innovative product developments, and expanding market presence, iRadimed is poised for continued success and value creation for shareholders.
Investors can be optimistic about iRadimed's performance, as the company demonstrates resilience, growth potential, and a solid foundation for future expansion.

iRadimed reports record Q3 earnings, raises 2023 guidance optimistically

iRadimed (IRMD) delivered exceptional Q3 '23 results, with record revenue, earnings growth, and strong product sales, positioning the company for continued success.
While facing challenges in meeting Q4 '23 targets and securing regulatory approvals, iRadimed's proactive strategies and market opportunities offer avenues for sustained growth.
With raised guidance for 2023 and promising product developments, iRadimed has the potential to capitalize on its strengths and navigate industry challenges effectively.
Investors and stakeholders can look to iRadimed's performance, product innovation, and regulatory progress as indicators of the company's resilience and growth prospects.

iRadimed (IRMD) reports record Q4 revenue, eyes international expansion

iRadimed's Q4 2023 performance marked by record revenue, strong device sales, and margin challenges. The company's focus on product growth and international expansion presents opportunities for future revenue and earnings growth.

iRadimed (IRMD) posts record revenue and earnings growth in Q1 2024

iRadimed (IRMD) delivered strong financial performance in Q1 2024, driven by record revenue, earnings growth, and robust demand for MR patient monitor products.
Despite challenges such as submission delays and significant investment in a new facility, the company remains focused on innovation and shareholder value.
With opportunities for market expansion, product clearance, and operational enhancements, iRadimed is poised for continued growth and competitive strength in the medical device industry.

iRadimed (IRMD) achieves record Q2 earnings, eyes FDA clearance

iRadimed's Q2 2024 performance reflects robust revenue growth, improved margins, and enhanced operational efficiency, positioning the company for continued success.
While facing challenges in international sales and operational delays, iRadimed's focus on cost management and product development presents opportunities for future growth.
Overall, iRadimed's financial outlook remains positive, with strong cash flow, new product developments, and strategic initiatives driving long-term value for investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

IRMD will soon report record revenue and improving margins for a fourth consecutive quarter.

Comparing IRadimed To Another Monopoly

WINTER SPRINGS, Fla., Oct.  08, 2019  (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that it received a close-out letter from the U.S. Food and Drug Administration resolving all issues cited in the August 2014 warning letter.

IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System

IRadimed is a leader in developing innovative MRI (Magnetic Resonance Imaging) compatible medical devices and accessories.

IRadimed: Expansion Is The Word

WINTER SPRINGS, Fla., Aug.  27, 2019  (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), today announced that Leslie McDonnell, President and Chief Executive Officer, Roger Susi, Chairman and Chief Technology Officer and Chris Scott, Chief Financial Officer, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference in New York from September 9, 2019 to September 11, 2019.

IRADIMED CORPORATION to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

IRadimed Corp (IRMD) CEO Roger Susi on Q2 2019 Results - Earnings Call Transcript

IRMD is the only known provider of non-magnetic MRI compatible products in the U.S.

iRadimed Corporation - Oversold Monopoly

IRadimed Corp (IRMD) CEO Roger Susi on Q1 2019 Results - Earnings Call Transcript

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRadimed (IRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

News for iRadimed Stock (IRMD)